PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is a 48-week prospective observational study that will allow testing of the hypothesis
that a program in which pre-exposure prophylaxis (PrEP) is administered to young men of color
who have sex with men (yMSMc) in a community youth drop-in center in conjunction with a
multifaceted behavioral intervention as well as standard HIV prevention interventions can
achieve at least 70% retention, as well as a medication adherence rate significantly better
than that previously reported in the literature. The proposed program evaluation can provide
critical information for the enhancement and scale-up of successful PrEP programs at FIGHT
and elsewhere in an effort to make PrEP available to a growing number of persons at risk of
acquiring human immunodeficiency virus (HIV).
Details
Lead Sponsor:
Philadelphia Fight
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir